Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors:
Safety, Efficacy, and Biomarkers.
Wang Y, Liu T, Chen G, Gong J, Bai Y, Zhang T, Xu N, Liu L, Xu J, He J, Liu Y, Zhang L, Jiang D, Wang M, Chang J, Li W, Bai C, Zhou J, Wang J, Ren Y, Zhang L, Su W, Liu B, Shen L.
Wang Y, et al. Among authors: wang j, wang m.
Oncologist. 2022 Apr 21;27(5):342-e383. doi: 10.1093/oncolo/oyab066. Online ahead of print.
Oncologist. 2022.
PMID: 35445725
Free PMC article.